Latest News and Press Releases
Want to stay updated on the latest news?
-
Repeat: EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025
Glasgow, Scotland – 2 May 2025. EnteroBiotix Limited (‘EnteroBiotix’), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that...
-
Glasgow, Scotland – 2 May 2025. EnteroBiotix Limited (‘EnteroBiotix’), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that...
-
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
-
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
-
EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy...